目的 探討瑞替普酶輔助治療腦缺血所致頭暈的效果。方法 2012年9月-2014年2月選擇河北省秦皇島市北戴河醫(yī)院收治的腦缺血所致頭暈患者120例,根據(jù)隨機(jī)抽簽原則分為治療組與對(duì)照組各60例,對(duì)照組給予常規(guī)治療,治療組在此基礎(chǔ)上加用瑞替普酶治療,均治療4周。結(jié)果 治療后治療組與對(duì)照組的有效率分別95.0%和83.3%,治療組明顯高于對(duì)照組(P<0.05)。兩組治療后的基底動(dòng)脈與椎動(dòng)脈血流速度都明顯增加(P<0.05),同時(shí)治療后治療組的基底動(dòng)脈與椎動(dòng)脈血流速度明顯高于對(duì)照組(P<0.05)。兩組治療后的ABCD2評(píng)分均明顯下降(P<0.05),與對(duì)照組相比,治療后治療組的ABCD2評(píng)分明顯較低(P<0.05)。結(jié)論 腦缺血所致頭暈在臨床上比較常見(jiàn),瑞替普酶的輔助治療能有效降低ABCD2評(píng)分,改善血流狀況,從而提高治療療效。

Objective To investigate the effects and related mechanisms of different medications for treating dizziness induced by cerebral ischemia. Methods From September 2012 to February 2014, selected 120 patients with dizziness induced by cerebral ischemia were equally divided into treatment group and control group based on the principle of a random draw, the patients in control group received conventional therapy, on the basis of the patients in treatment group were treated with reteplase treatment. Results After treatment, the efficiencies in the treatment group and the control group were 95.0% and 83.3% with statistically significant difference between two groups (P < 0.05). The blood flow velocities of basilar artery and vertebral artery in two groups after treatment were significantly increased (P < 0.05), while the blood flow velocities of basilar artery and vertebral artery in the treatment group were significantly higher (P < 0.05). After treatment, the ABCD2 scores were significantly decreased (P < 0.05), but ABCD2 score in treatment group was significantly lower than that in the control group (P < 0.05). Conclusion Cerebral ischemia-induced dizziness is more common in clinical practice, and reteplase adjuvant therapy can effectively reduce ABCD2 score, improve blood flow, thereby improve therapeutic efficacy.

秦皇島市科技支撐計(jì)劃項(xiàng)目(201302A185)